ABG Innovation Capital Partners III GP Ltd Long-Term Concentrated

Name: ABG Innovation Capital Partners III GP Ltd Q1 2022 13F Filing | 13F Explorer
Creator: ABG Innovation Capital Partners III GP Ltd
Published: 2022-05-16

Location: Central, Hong Kong, Hong Kong

CIK: 0001845297 · Show all filings

Period: Q1 2022 (← Previous) (Next →)

Filing Date: May 16, 2022

Total Value: $1.463M (100.0% shares, 0.0% debt)

Holdings (5)

— SYNLOGIC INC 33.8%

Value $494K Shares 205,906 Est. Cost $2.16 Unrealized —

GNCAQ GENOCEA BIOSCIENCES INC 32.1%

Value $469K Shares 375,000 Est. Cost $2.28 Unrealized -52.2%

WHWK AADI BIOSCIENCES INC 31.0%

Value $453K Shares 26,666 Est. Cost $30.48 Unrealized -37.1%

— IDERA PHARMACEUTICALS INC 1.9%

Value $28,000 Shares 56,250 Est. Cost $3.66 Unrealized —

— NABRIVA THERAPEUTICS PLC 1.3%

Value $19,000 Shares 45,849 Est. Cost $2.42 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	SYNLOGIC INC	205,906	$494K	33.8%	$2.16	—	COM	87166L100
GNCAQ	GENOCEA BIOSCIENCES INC	375,000	$469K	32.1%	$2.28	-52.2%	COM NEW	372427401
WHWK	AADI BIOSCIENCES INC	26,666	$453K	31.0%	$30.48	-37.1%	COM	00032Q104
—	IDERA PHARMACEUTICALS INC	56,250	$28,000	1.9%	$3.66	—	COM PAR	45168K405
—	NABRIVA THERAPEUTICS PLC	45,849	$19,000	1.3%	$2.42	—	SHS	G63637113